Ultra-small superparamagnetic iron oxides for metastatic lymph node detection: back on the block

Area of Science:

• Nanomedicine and Nanodiagnostics
• Oncologic Imaging

Background:

• Combidex-enhanced MRI (CEM) previously demonstrated significant clinical efficacy for detecting small lymph node metastases.
• The withdrawal of Combidex (ferumoxtran-10) limited its use, necessitating invasive surgical exploration for lymph node evaluation, especially in prostate cancer patients.
• Radboud University Medical Center (Radboudumc) has resumed the production and clinical use of Combidex since 2013.

Purpose of the Study:

• To review the working mechanism, historical efficacy, and safety of Combidex-enhanced MRI (CEM).
• To highlight the reintroduction of Combidex in the Netherlands and its application in prostate cancer diagnostics.
• To discuss the future perspectives of CEM as a diagnostic tool.

Main Methods:

• Review of clinical data and literature on Combidex-enhanced MRI (CEM).
• Analysis of patient data from Radboudumc, including 310 men with prostate cancer examined since 2014.
• Monitoring and reporting of adverse effects related to Combidex administration.

Main Results:

• Since reintroduction in 2014, 310 men with prostate cancer have been evaluated using CEM at Radboudumc.
• Seven minor adverse effects, possibly related to Combidex, were observed in this cohort.
• CEM continues to offer a more accurate alternative to conventional imaging for lymph node assessment.

Conclusions:

• Combidex-enhanced MRI (CEM) is a safe and effective diagnostic tool for lymph node metastases, particularly in prostate cancer.
• The reintroduction of Combidex provides a crucial non-invasive imaging option, reducing the need for diagnostic surgery.
• Further utilization and research into CEM hold promise for improving oncologic diagnostics.